SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Michael J. Hurley, Pascal F. Durrenberger, Steve M. Gentleman, Andrew F. Walls, David T. Dexter, Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson’s Disease, Journal of Molecular Neuroscience, 2015,

    CrossRef

  2. 2
    C.K. Firoz, Nasimudeen R. Jabir, Mohd Shahnawaz Khan, Maged Mahmoud, Shazi Shakil, Ghazi A. Damanhouri, Syed Kashif Zaidi, Shams Tabrez, Mohammad A. Kamal, An overview on the correlation of neurological disorders with cardiovascular disease, Saudi Journal of Biological Sciences, 2015, 22, 1, 19

    CrossRef

  3. 3
    Reversa Mills, Laxman Bahroo, Fernando Pagan, An Update on the Use of Botulinum Toxin Therapy in Parkinson’s Disease, Current Neurology and Neuroscience Reports, 2015, 15, 1

    CrossRef

  4. 4
    Nathan C. Rowland, Philip A. Starr, Paul S. Larson, Jill L. Ostrem, William J. Marks, Daniel A. Lim, Combining cell transplants or gene therapy with deep brain stimulation for Parkinson's disease, Movement Disorders, 2015, 30, 2
  5. 5
    Chandana Buddhala, Meghan C. Campbell, Joel S. Perlmutter, Paul T. Kotzbauer, Correlation between decreased CSF α-synuclein and Aβ1–42 in Parkinson disease, Neurobiology of Aging, 2015, 36, 1, 476

    CrossRef

  6. 6
    Gil Van Bokkelen, Manal Morsy, Toshi-hiko Kobayashi, Demographic Transition, Health Care Challenges, and the Impact of Emerging International Regulatory Trends With Relevance to Regenerative Medicine, Current Stem Cell Reports, 2015,

    CrossRef

  7. 7
    Spyros Papapetropoulos, Georgia Mitsi, Alberto J. Espay, Digital Health Revolution: Is it Time for Affordable Remote Monitoring for Parkinson’s Disease?, Frontiers in Neurology, 2015, 6,

    CrossRef

  8. 8
    X. Lei, B. Huang, H. Li, H. Jiang, X. Hu, B. Zhang, Drift in centrality of different brain regions in an anatomical neural network with Parkinson’s disease: A view from complex network analysis, Neuroscience, 2015, 299, 107

    CrossRef

  9. 9
    Roeland Vanhauwaert, Patrik Verstreken, Flies with Parkinson's disease, Experimental Neurology, 2015,

    CrossRef

  10. 10
    Benjamin H.M. Hunn, Stephanie J. Cragg, J. Paul Bolam, Maria-Grazia Spillantini, Richard Wade-Martins, Impaired intracellular trafficking defines early Parkinson's disease, Trends in Neurosciences, 2015, 38, 3, 178

    CrossRef

  11. 11
    Ashish Kumar Kakkar, Neha Dahiya, Management of Parkinson׳s disease: Current and future pharmacotherapy, European Journal of Pharmacology, 2015, 750, 74

    CrossRef

  12. 12
    David J. Mc Carthy, Meenakshi Malhotra, Aoife M. O’Mahony, John F. Cryan, Caitriona M. O’Driscoll, Nanoparticles and the Blood-Brain Barrier: Advancing from In-Vitro Models Towards Therapeutic Significance, Pharmaceutical Research, 2015, 32, 4, 1161

    CrossRef

  13. 13
    Jin-Cherng Chen, Tzung-Yi Tsai, Chung-Yi Li, Juen-Haur Hwang, Obstructive sleep apnea and risk of Parkinson's disease: a population-based cohort study, Journal of Sleep Research, 2015, 24, 3
  14. 14
    Nawaz Hack, Umer Akbar, Erin H. Monari, Amanda Eilers, Amanda Thompson-Avila, Nelson H. Hwynn, Ashok Sriram, Ihtsham Haq, Angela Hardwick, Irene A. Malaty, Michael S. Okun, Person-Centered Care in the Home Setting for Parkinson’s Disease: Operation House Call Quality of Care Pilot Study, Parkinson's Disease, 2015, 2015, 1

    CrossRef

  15. 15
    Douglas R. Seals, Jamie N. Justice, Thomas J. LaRocca, Physiological geroscience: targeting function to increase healthspan and achieve optimal longevity, The Journal of Physiology, 2015, 593, 10
  16. 16
    Andrew B. West, Ten Years and Counting: Moving Leucine-Rich RepeatKinase 2 Inhibitors to the Clinic, Movement Disorders, 2015, 30, 2
  17. 17
    Matthew Gladman, Lorne Zinman, The economic impact of amyotrophic lateral sclerosis: a systematic review, Expert Review of Pharmacoeconomics & Outcomes Research, 2015, 15, 3, 439

    CrossRef

  18. 18
    L. L. Kubik, M. A. Philbert, The Role of Astrocyte Mitochondria in Differential Regional Susceptibility to Environmental Neurotoxicants: Tools for Understanding Neurodegeneration, Toxicological Sciences, 2015, 144, 1, 7

    CrossRef

  19. 19
    Andrew Siderowf, Bridging the credibility gap in cost effectiveness analysis, Movement Disorders, 2014, 29, 2
  20. 20
    Cheng-long Xie, Wen-Wen Wang, Su-fang Zhang, Jing Gan, Zhen-Guo Liu, Continuous dopaminergic stimulation (CDS)-based treatment in Parkinson's disease patients with motor complications: A systematic review and meta-analysis, Scientific Reports, 2014, 4,

    CrossRef

  21. 21
    Kevin T. Stroupe, Frances M. Weaver, Lishan Cao, Dolores Ippolito, Brandon R. Barton, Inger E. Burnett-Zeigler, Robert G. Holloway, Barbara G. Vickrey, Tanya Simuni, Kenneth A. Follett, Cost of deep brain stimulation for the treatment of Parkinson's disease by surgical stimulation sites, Movement Disorders, 2014, 29, 13
  22. 22
    Tejas Sankar, Nir Lipsman, Andres M. Lozano, Deep Brain Stimulation for Disorders of Memory and Cognition, Neurotherapeutics, 2014, 11, 3, 527

    CrossRef

  23. 23
    Paul S. Larson, Deep Brain Stimulation for Movement Disorders, Neurotherapeutics, 2014, 11, 3, 465

    CrossRef

  24. 24
    Khashayar Dashtipour, Do genetic factors protect against Parkinson’s disease? What I can learn from my healthy grandma, Medical Hypotheses, 2014, 83, 6, 637

    CrossRef

  25. 25
    A. Park, D. Zid, J. Russell, A. Malone, A. Rendon, A. Wehr, X. Li, Effects of a formal exercise program on Parkinson's disease: A pilot study using a delayed start design, Parkinsonism & Related Disorders, 2014, 20, 1, 106

    CrossRef

  26. 26
    Xiao-Li Wang, Gui-Hua Xing, Bo Hong, Xiao-Ming Li, Yu Zou, Xiao-Jie Zhang, Miao-Xian Dong, Gastrodin prevents motor deficits and oxidative stress in the MPTP mouse model of Parkinson's disease: Involvement of ERK1/2–Nrf2 signaling pathway, Life Sciences, 2014, 114, 2, 77

    CrossRef

  27. 27
    Erwin E. H. van Wegen, Mark A. Hirsch, Marijn Huiskamp, Gert Kwakkel, Harnessing Cueing Training for Neuroplasticity in Parkinson Disease, Topics in Geriatric Rehabilitation, 2014, 30, 1, 46

    CrossRef

  28. 28
    Cecilia Davis, Jeremy Mudd, Meredith Hawkins, Neuroprotective effects of leptin in the context of obesity and metabolic disorders, Neurobiology of Disease, 2014, 72, 61

    CrossRef

  29. 29
    Mark A. Hirsch, Mohammed Sanjak, Danielle Englert, Sanjay Iyer, Margaret M. Quinlan, Parkinson patients as partners in care, Parkinsonism & Related Disorders, 2014, 20, S174

    CrossRef

  30. 30
    Chava Peretz, Orly Chillag-Talmor, Shai Linn, Tanya Gurevich, Baruch El-Ad, Barbara Silverman, Nurit Friedman, Nir Giladi, Parkinson's disease patients first treated at age 75 years or older: A comparative study, Parkinsonism & Related Disorders, 2014, 20, 1, 69

    CrossRef

  31. 31
    A. Garcia-Cazorla, S. T. Duarte, Parkinsonism and inborn errors of metabolism, Journal of Inherited Metabolic Disease, 2014, 37, 4, 627

    CrossRef

  32. 32
    Beth-Anne Sieber, Story Landis, Walter Koroshetz, Randall Bateman, Andrew Siderowf, Wendy R. Galpern, John Dunlop, Steven Finkbeiner, Margaret Sutherland, Hao Wang, Virginia M.-Y. Lee, Harry T. Orr, Katrina Gwinn, Kip Ludwig, Anna Taylor, Christine Torborg, Thomas J. Montine, Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson'sDisease 2014 conference, Annals of Neurology, 2014, 76, 4
  33. 33
    Arturo Benitez, Heather Edens, Jesse Fishman, Kimberly Moran, Mahnaz Asgharnejad, Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome, Annals of the New York Academy of Sciences, 2014, 1329, 1
  34. 34
    Michal Lubomski, R. Louise Rushworth, Will Lee, Kelly L. Bertram, David R. Williams, Sex differences in Parkinson’s disease, Journal of Clinical Neuroscience, 2014, 21, 9, 1503

    CrossRef

  35. 35
    A. Zara Herskovits, Leonard Guarente, SIRT1 in Neurodevelopment and Brain Senescence, Neuron, 2014, 81, 3, 471

    CrossRef

  36. 36
    T. L. Pitcher, M. R. MacAskill, T. J. Anderson, Trends in Antiparkinsonian Medication Use in New Zealand: 1995–2011, Parkinson's Disease, 2014, 2014, 1

    CrossRef

  37. 37
    Alice S. Chen-Plotkin, Unbiased Approaches to Biomarker Discovery in Neurodegenerative Diseases, Neuron, 2014, 84, 3, 594

    CrossRef

  38. 38
    Katherine L. Baquerizo Nole, Elizabeth Yim, Freya Van Driessche, Jeffrey M. Davidson, Manuela Martins-Green, Chandan K. Sen, Marjana Tomic-Canic, Robert S. Kirsner, Wound research funding from alternative sources of federal funds in 2012, Wound Repair and Regeneration, 2014, 22, 3
  39. 39
    Suneil K. Kalia, Tejas Sankar, Andres M. Lozano, Deep brain stimulation for Parkinsonʼs disease and other movement disorders, Current Opinion in Neurology, 2013, 26, 4, 374

    CrossRef

  40. 40
    Paul H Gordon, The murky path to drug discovery in ALS becomes clearer, The Lancet Neurology, 2013, 12, 11, 1037

    CrossRef